RetinalGenix Technologies Inc. financial data

Symbol
RTGN on OTC
Industry
Surgical & Medical Instruments & Apparatus
Location
1450 North Mcdowell Boulevard, Suite 150, Petaluma, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -104 % -3.45%
Return On Equity 260 % +79.2%
Return On Assets -7.16K % +91.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.5M shares +4.14%
Common Stock, Shares, Outstanding 18.5M shares +5.03%
Entity Public Float 15.5M USD 0%
Common Stock, Value, Issued 1.85K USD +4.99%
Weighted Average Number of Shares Outstanding, Basic 17.9M shares +3.39%
Weighted Average Number of Shares Outstanding, Diluted 17.9M shares +3.39%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 153K USD +12.7%
General and Administrative Expense 1.33M USD +48.4%
Net Income (Loss) Attributable to Parent -4.32M USD -107%
Earnings Per Share, Basic -0.24 USD/shares -100%
Earnings Per Share, Diluted -0.24 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 44 USD -98.8%
Assets, Current 6.06K USD
Property, Plant and Equipment, Net 56 USD -64.1%
Operating Lease, Right-of-Use Asset 6.84K USD
Assets 14.9K USD +9481%
Liabilities, Current 1.47M USD +4.64%
Operating Lease, Liability, Noncurrent 6.54K USD
Liabilities 1.48M USD +5.1%
Retained Earnings (Accumulated Deficit) -15.4M USD -38.9%
Stockholders' Equity Attributable to Parent -1.46M USD -4.05%
Liabilities and Equity 14.9K USD +9481%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -143K USD -84.2%
Net Cash Provided by (Used in) Financing Activities 193K USD +127%
Common Stock, Shares Authorized 80M shares 0%
Common Stock, Shares, Issued 18.5M shares +5.03%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.4K USD +578%
Deferred Tax Assets, Valuation Allowance 4.61M USD +39.1%
Deferred Tax Assets, Gross 4.61M USD +39.1%
Operating Lease, Liability 7.53K USD
Depreciation 25 USD 0%
Lessee, Operating Lease, Liability, to be Paid 21.5K USD
Operating Lease, Liability, Current 988 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.11K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 7.88K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.52K USD
Deferred Tax Assets, Operating Loss Carryforwards 1.77M USD +23.3%
Preferred Stock, Shares Authorized 40M shares 0%
Operating Lease, Payments 7.69K USD
Additional Paid in Capital 14.1M USD +45.5%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 3.84K USD -17.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%